93 related articles for article (PubMed ID: 17603925)
1. Highlight Commentary on "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis".
Calabrese V
Free Radic Biol Med; 2007 Jul; 43(2):160-2. PubMed ID: 17603925
[TBL] [Abstract][Full Text] [Related]
2. Familial amyotrophic lateral sclerosis (FALS): Emerging hints from redox proteomics. Highlight commentary on: "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis".
Dalle-Donne I
Free Radic Biol Med; 2007 Jul; 43(2):157-9. PubMed ID: 17603924
[No Abstract] [Full Text] [Related]
3. Good science shows the way. Highlight Commentary on "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis".
Estévez AG
Free Radic Biol Med; 2007 Jul; 43(2):163-4. PubMed ID: 17603926
[No Abstract] [Full Text] [Related]
4. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis.
Poon HF; Hensley K; Thongboonkerd V; Merchant ML; Lynn BC; Pierce WM; Klein JB; Calabrese V; Butterfield DA
Free Radic Biol Med; 2005 Aug; 39(4):453-62. PubMed ID: 16043017
[TBL] [Abstract][Full Text] [Related]
5. Mutation of superoxide dismutase elevates reactive species: comparison of nitration and oxidation of proteins in different brain regions of transgenic mice with amyotrophic lateral sclerosis.
Liu D; Bao F; Wen J; Liu J
Neuroscience; 2007 Apr; 146(1):255-64. PubMed ID: 17368952
[TBL] [Abstract][Full Text] [Related]
6. [Amyotrophic lateral sclerosis: recent insights from transgenic animal models with SOD1 mutations].
Aoki M
Rinsho Shinkeigaku; 2004 Nov; 44(11):788-91. PubMed ID: 15651292
[TBL] [Abstract][Full Text] [Related]
7. Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice.
Pardo AC; Wong V; Benson LM; Dykes M; Tanaka K; Rothstein JD; Maragakis NJ
Exp Neurol; 2006 Sep; 201(1):120-30. PubMed ID: 16753145
[TBL] [Abstract][Full Text] [Related]
8. Reduction of axonal caliber does not alleviate motor neuron disease caused by mutant superoxide dismutase 1.
Nguyen MD; Larivière RC; Julien JP
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12306-11. PubMed ID: 11050249
[TBL] [Abstract][Full Text] [Related]
9. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).
Howland DS; Liu J; She Y; Goad B; Maragakis NJ; Kim B; Erickson J; Kulik J; DeVito L; Psaltis G; DeGennaro LJ; Cleveland DW; Rothstein JD
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1604-9. PubMed ID: 11818550
[TBL] [Abstract][Full Text] [Related]
10. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.
Turner BJ; Talbot K
Prog Neurobiol; 2008 May; 85(1):94-134. PubMed ID: 18282652
[TBL] [Abstract][Full Text] [Related]
11. Gender difference in levels of Cu/Zn superoxide dismutase (SOD1) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Frutiger K; Lukas TJ; Gorrie G; Ajroud-Driss S; Siddique T
Amyotroph Lateral Scler; 2008 Jun; 9(3):184-7. PubMed ID: 18574763
[TBL] [Abstract][Full Text] [Related]
12. Mutant mice, Cu,Zn superoxide dismutase, and motor neuron degeneration.
McCord JM
Science; 1994 Dec; 266(5190):1586-7. PubMed ID: 7985031
[No Abstract] [Full Text] [Related]
13. Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis.
Gomes C; Keller S; Altevogt P; Costa J
Neurosci Lett; 2007 Nov; 428(1):43-6. PubMed ID: 17942226
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis.
Ohta Y; Kamiya T; Nagai M; Nagata T; Morimoto N; Miyazaki K; Murakami T; Kurata T; Takehisa Y; Ikeda Y; Asoh S; Ohta S; Abe K
J Neurosci Res; 2008 Oct; 86(13):3028-37. PubMed ID: 18543336
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pathological alterations in ALS and a murine transgenic model: pathogenetic implications.
Dal Canto MC
Clin Neurosci; 1995-1996; 3(6):332-7. PubMed ID: 9021254
[TBL] [Abstract][Full Text] [Related]
16. Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis.
Chritin M; Savasta M; Besson G
Amyotroph Lateral Scler; 2006 Mar; 7(1):32-7. PubMed ID: 16546757
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathological study of patient with familial amyotrophic lateral sclerosis associated with a two-base pair deletion in the copper/zinc superoxide dismutase (SOD1) gene.
Kadekawa J; Fujimura H; Yanagihara T; Sakoda S
Acta Neuropathol; 2001 Apr; 101(4):415. PubMed ID: 11355314
[No Abstract] [Full Text] [Related]
18. [Amyotrophic lateral sclerosis and cognitive disorders: review and analysis of the literature].
Portet F; Touchon J; Camu W
Rev Neurol (Paris); 2001 Feb; 157(2):139-50. PubMed ID: 11283461
[TBL] [Abstract][Full Text] [Related]
19. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies.
Gurney ME
J Neurol Sci; 1997 Oct; 152 Suppl 1():S67-73. PubMed ID: 9419057
[TBL] [Abstract][Full Text] [Related]
20. Fragmentation of the Golgi apparatus of the anterior horn cells in patients with familial amyotrophic lateral sclerosis with SOD1 mutations and posterior column involvement.
Fujita Y; Okamoto K; Sakurai A; Gonatas NK; Hirano A
J Neurol Sci; 2000 Mar; 174(2):137-40. PubMed ID: 10727699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
